Investors have funneled $275 million into a revamped biotech developing new psoriasis and psoriatic arthritis treatments that could be given just once or twice a year.
The new Oruka Therapeutics launched Wednesday through a reverse merger with ARCA biopharma, a Colorado biotech that has undergone several iterations over the last 30 years. With the merger, ARCA’s plans are being cast aside in favor of Oruka’s antibody medicines, which came from spinout-generator Paragon Therapeutics. Over the last two years, Paragon has spun out Apogee Therapeutics and Spyre Therapeutics.
advertisement
Oruka will trade under the Nasdaq ticker “ORKA.”
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
Monthly
$39
Totals $468 per year
$39/month Get StartedTotals $468 per year
Starter
$30
for 3 months, then $39/month
$30 for 3 months Get StartedThen $39/month
Annual
$399
Save 15%
$399/year Get StartedSave 15%
11+ Users
Custom
Savings start at 25%!
Request A Quote Request A QuoteSavings start at 25%!
2-10 Users
$300
Annually per user
$300/year Get Started$300 Annually per user
View All Plans
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
After a decade, new Gardasil ad campaign gets it (mostly) right
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
